1258451-22-7

Upstream product

• 108-98-5 thiophenol 

Downstream Products

• 1258444-72-2 (1R,2R,4R)-4-(benzenesulfonyl)-2-N-(1-cyanocyclopropyl)-1-N,1-N-dimethylcyclopentane-1,2-dicarboxamide 
• 1258444-40-4 (1R,2R,4R)-4-(benzenesulfonyl)-N-(1-cyanocyclopropyl)-2-[(3-hydroxyazetidin-1-yl)carbonyl]cyclopentane-1-carboxamide 
• 1258444-67-5 (1R,2R,4R)-4-(benzenesulfonyl)-N-(1-cyanocyclopropyl)-2-[(pyrrolidin-1-yl)carbonyl]cyclopentane-1-carboxamide 
• 1258444-63-1 (1R,2R,4R)-4-(benzenesulfonyl)-N-(1-cyanocyclopropyl)-2-[(pyrrolidin-1-yl)carbonyl]cyclopentane-1-carboxamide 
• 1258444-87-9 (1R,2R,4S)-4-(benzenesulfonyl)-N₂-(1-cyanocyclopropyl)-N₁-(4-fluorophenyl)cyclopentane-1,2-dicarboxamide 
• 1258444-53-9 (1R,2R,4R)-4-(benzenesulfonyl)-N-(1-cyanocyclopropyl)-2-(1,1-dioxo-1-thiomorpholine-4-carbonyl)cyclopentanecarboxamide 
• 1258444-36-8 (1R,2R,4R)-4-(benzenesulfonyl)-N-(1-cyanocyclopropyl)-2-[(4-hydroxypiperidin-1-yl)carbonyl]cyclopentane-1-carboxamide 
• 1258444-38-0 (1R,2R,4R)-4-(benzenesulfonyl)-N-(1-cyanocyclopropyl)-2-[(piperazin-1-yl)carbonyl]cyclopentane-1-carboxamide 
• 1258444-71-1 (1R,2R,4R)-4-(benzenesulfonyl)-N-(1-cyanocyclopropyl)-2-[(4-methylpiperazin-1-yl)carbonyl]cyclopentane-1-carboxamide 
• 1258444-50-6 (1R,2R,4R)-4-(benzenesulfonyl)-N-(1-cyanocyclopropyl)-2-[(4-methylpiperidin-1-yl)carbonyl]cyclopentane-1-carboxamide 
• 1258444-33-5 (1R,2R,4R)-4-(benzenesulfonyl)-N-(1-cyanocyclopropyl)-2-[(piperidin-1-yl)carbonyl]cyclopentane-1-carboxamide 
• 1258444-30-2 (1R,2R,4R)-4-(benzenesulfonyl)-N-(1-cyanocyclopropyl)-2-({2-oxa-6-azaspiro[3.3]heptan-6-yl}carbonyl)cyclopentane-1-carboxamide 
• 1258444-43-7 (1R,2R,4R)-4-(benzenesulfonyl)-N-(1-cyanocyclopropyl)-2-{[(2S,6R)-2,6-dimethylmorpholin-4-yl]carbonyl}cyclopentane-1-carboxamide 
• 1258444-28-8 (1R,2R,4R)-4-benzenesulfonyl-2-(1-cyanocyclopropylcarbamoyl)cyclopentanecarboxylic acid 

Relevant academic research and scientific papers

Identification of potent and selective cathepsin S inhibitors containing different central cyclic scaffolds

Starting from the weakly active dual CatS/K inhibitor 5, structure-based design supported by X-ray analysis led to the discovery of the potent and selective (>50 000-fold vs CatK) cyclopentane derivative 22 by exploiting specific ligand-receptor interactions in the S2 pocket of CatS. Changing the central cyclopentane scaffold to the analogous pyrrolidine derivative 57 decreased the enzyme as well as the cell-based activity significantly by 24- and 69-fold, respectively. The most promising scaffold identified was the readily accessible proline derivative (e.g., 79). This compound, with an appealing ligand efficiency (LE) of 0.47, included additional structural modifications binding in the S1 and S3 pockets of CatS, leading to favorable in vitro and in vivo properties. Compound 79 reduced IL-2 production in a transgenic DO10.11 mouse model of antigen presentation in a dose-dependent manner with an ED 50 of 5 mg/kg.

NOVEL CYCLOPENTANE DERIVATIVES

The invention relates to a compound of formula (I) wherein A1 and R1 to R5 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.